Acute poisoning by arsenic, mercury and gold salts

Signal poisoning, severe in association with E.D.T.A., Calcicodisodic.

Parenteral: pathway, strict intramuscular.
The dose is 3 mg / kg per injection for an adult of about 70 kg

· The first 2 days: 1 injection every 4 hours, that is 6 injections

· On the third day: 1 injection every 6 hours, that is 4 injections

· The following 10 days: 2 injections per day.

In acute mercury nephritis (in the absence of anuria see Warnings and Precautions: 5 mg / kg and per injection)

Begin the treatment with 1/4 ampoule (50 mg) to look for individual sensitivity of the patient

As for any non-aqueous injectable solution, administer by means of a glass syringe.
Pharmacotherapeutic group, ANTIDOTE, ATC code: V03AB09

(V: miscellaneous)

Dimercaprol combines with arsenic, mercury or gold

It has a greater affinity than the proteins for these metals and forms with them a stable compound, rapidly excreted, by the kidney.

This medication is contraindicated in cases of

· Hypersensitivity to dimercaprol and to butacaine or any of the other ingredients of the injectable solution

Special warnings

The toxicity of this drug (in relation to its reducing power) is increased in case of renal or hepatic impairment

It should therefore be administered with caution in patients with renal or hepatic impairment

Precautions should also be taken in patients with hypertension (see section Effects, undesirable).

In case of G6PD deficiency, this drug may cause hemolysis.
Precautions for use

The injection should be done strictly: intramuscularly and with a glass syringe

The use of dimercaprol in acute mercurial nephritis will only occur in the absence of anuria.
The attention of athletes will be drawn to the fact that this specialty contains an active ingredient (local anesthetic) which can induce a positive reaction of the tests carried out during the anti-doping tests.

Without object.

In the absence of compatibility studies, this drug should not be mixed with other medicines.
In case of overdose, hypertension, convulsions, and coma have been observed.

Studies carried out in the animal have demonstrated a teratogenic effect.

There is currently no relevant or sufficient data to evaluate a possible malformative or fetotoxic effect of dimercaprol when administered during pregnancy.

Accordingly, in the light of these data and the indication, this combination may be prescribed during pregnancy if necessary.


Due to the lack of data on the use of this medicinal product in breast milk, breast-feeding should be avoided during the use of this product.
· Injection site pain

· Hypertension, tachycardia

Nausea, vomiting, headache, sensation, burning of the face

Acute poisoning by arsenic, mercury and gold salts, Saturnine poisoning, severe in association with E.D.T.A., calcicodisodic